Zevra Therapeutics, Inc. Proceeds from Lines of Credit
Zevra Therapeutics, Inc. (ZVRA) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2022-03-31
- Zevra Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2021-12-31 was $0.00.
- Zevra Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2021-09-30 was $0.00.
- Zevra Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2020-12-31 was $0.00.
- Zevra Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. proceeds from lines of credit for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Zevra Therapeutics, Inc. proceeds from lines of credit for fiscal 2020 was $2.30M, a 57.71% decline from fiscal 2019.
- Zevra Therapeutics, Inc. proceeds from lines of credit for fiscal 2019 was $5.45M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $1.19M derived: sum of 3 quarters · filed 2022-03-31 | $2.30M 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.19M derived: sum of 2 quarters · filed 2021-11-10 | $2.30M 10-Q · filed 2021-11-10 | $2.30M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $2.30M 10-Q · filed 2021-08-13 | $2.30M derived: sum of 3 quarters · filed 2021-08-13 | $3.80M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $1.11M 10-Q · filed 2021-05-14 | $1.11M derived: sum of 2 quarters · filed 2021-05-14 | $2.61M derived: sum of 3 quarters · filed 2021-05-14 | $3.84M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $1.50M derived: sum of 2 quarters · filed 2021-03-12 | $2.73M derived: sum of 3 quarters · filed 2021-03-12 | $5.45M 10-K · filed 2021-03-12 |
| 2019-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $2.73M derived: sum of 2 quarters · filed 2020-10-30 | $5.45M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $3.95M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $2.72M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |